Zhitong Finance App News, Shiyao Group (01093.HK) announced that the phase II clinical trial (SYH2072-003) of SYH2072 tablets (this product) developed by the Group for the treatment of uncontrolled and refractory hypertension (SYH2072-003) has been officially launched at the first research center in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.